Invesco Ltd. Biocryst Pharmaceuticals Inc Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Invesco Ltd. holds 993,117 shares of BCRX stock, worth $8.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

993,117

Previous 968,155 2.58%

Holding current value

$8.29 Million

Previous $7.26 Million 22.55%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$6.41 - $11.19 $160,006 - $279,324	24,962 Added 2.58%	993,117 $8.9 Million
Q1 2025 May 12, 2025	SELL	$7.06 - $9.39 $737,381 - $980,738	-104,445 Reduced 9.74%	968,155 $7.26 Million
Q4 2024 Feb 13, 2025	BUY	$7.03 - $8.43 $474,468 - $568,957	67,492 Added 6.71%	1,072,600 $8.07 Million
Q3 2024 Nov 12, 2024	BUY	$6.41 - $8.69 $5.79 Million - $7.85 Million	903,185 Added 886.14%	1,005,108 $7.64 Million
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $10,374 - $17,056	2,512 Added 2.53%	101,923 $629,000
Q1 2024 May 14, 2024	BUY	$4.89 - $7.65 $9,647 - $15,093	1,973 Added 2.02%	99,411 $505,000
Q4 2023 Feb 12, 2024	SELL	$4.98 - $6.77 $12,435 - $16,904	-2,497 Reduced 2.5%	97,438 $583,000
Q3 2023 Nov 13, 2023	SELL	$6.71 - $7.92 $1,966 - $2,320	-293 Reduced 0.29%	99,935 $707,000
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $23,162 - $29,319	3,328 Added 3.43%	100,228 $705,000
Q1 2023 May 12, 2023	SELL	$7.94 - $11.84 $2.07 Million - $3.08 Million	-260,155 Reduced 72.86%	96,900 $808,000
Q4 2022 Feb 13, 2023	SELL	$10.5 - $14.2 $58,243 - $78,767	-5,547 Reduced 1.53%	357,055 $4.1 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $877,507 - $1.2 Million	81,326 Added 28.91%	362,602 $4.57 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $457,588 - $1.04 Million	57,996 Added 25.97%	281,276 $2.98 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $217,963 - $372,574	18,855 Added 9.22%	223,280 $3.63 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $44,038 - $60,896	-3,939 Reduced 1.89%	204,425 $2.83 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $7.73 Million - $9.6 Million	-543,748 Reduced 72.3%	208,364 $3 Million
Q2 2021 Aug 17, 2021	SELL	$9.5 - $17.24 $6.48 Million - $11.8 Million	-681,726 Reduced 47.55%	752,112 $11.9 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $10.3 Million - $19 Million	1,396,756 Added 3766.67%	1,433,838 $14.6 Million
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $84,883 - $216,868	25,188 Added 211.77%	37,082 $276,000
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $1,478 - $2,383	431 Added 3.76%	11,894 $41,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $21,779 - $64,307	11,463 New	11,463 $55,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $3.62 Million - $5.4 Million	-1,446,732 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $1.64 Million - $5.16 Million	563,822 Added 63.86%	1,446,732 $5.48 Million
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $898,994 - $1.18 Million	-121,815 Reduced 12.12%	882,910 $7.19 Million
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $6.54 Million - $9.65 Million	1,004,725 New	1,004,725 $8.11 Million

Others Institutions Holding BCRX

# of Institutions

316

Shares Held

202M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.55B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account